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Purpose: To validate a third generation performance based measure of visual function titled the 
“Assessment of Disability Related to Vision” (ADREV) in a study population of patients with diabetic 
retinopathy. 
Design: Prospective, cross-sectional study. 
Methods: Patients with non-proliferative or proliferative diabetic retinopathy, free from ocular comorbidity 
were recruited from a single institute and completed the ADREV, the 25-Item National Eye Institute’s 
Visual Functioning Questionnaire (VFQ), and a clinical ophthalmic examination. Correlation, regression 
and bootstrap analysis were conducted to determine the relationship between ADREV scoring and each 
of the study’s clinical and self-report measures of visual ability, while controlling for potential confounders. 
Results: 91 patients with diabetic retinopathy completed the study and analysis showed that the ADREV 
total and subscale scores shared a stronger relationship with the clinical measures of visual function than 
did the VFQ total and subscale scores. Regression analysis revealed that binocular visual acuity, contrast 
sensitivity and better eye visual field were the best predictors of ADREV performance. 
Conclusions: The ADREV performance measure is a valid instrument for the assessment of disability 
related to vision in patients with diabetic retinopathy. Furthermore, the assessments provided by ADREV 
were more related to traditional clinical indicators of visual impairment than were the results of the self-
report measure, specifically, the VFQ-25. 
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Introduction 
Assessing visual health is a fundamental goal of ophthalmic practice. How one defines visual health has 
important implications for how it is measured and appraised. While the definition of health is subject to 
extensive debate, most individuals can agree that health involves the ability of an individual to perform 
common activities essential to modern life. Indeed, few would contest the idea that one lacks some 
measure of health if they are unable to perform essential activities of daily living such as walking, 
recognizing friendly faces and finding dropped items. While these ideas seem self-evident, the 
assessment of one’s ability to perform activities of daily living is rarely used to assess visual health. 
Traditional assessments of vision typically involve four types of information: 1) symptoms acquired 
through a medical history; 2) signs obtained through physical examination; 3) laboratory data; and 4) 
anatomic data acquired through various imaging modalities. Importantly, the advancement of modern 
biotechnology has provided novel methods of technology-intensive evaluations in the form of more 
sensitive imaging and laboratory assessments of visual health, such as confocal scanning laser 
ophthalmoscopy, optical coherence tomography and genetic analysis. However, it is evident that the 
results of these high-technology assessments are often unrelated to one’s ability to carry out daily 
activities. The disjunction between the current trend of high-technology assessment and the ability to 
function at a practical level is representative of the often encountered discrepancy between what is 
important to clinicians and what is important to patients. 
 
Over the last decade the discipline of visual health sciences has seen the growing use of standardized 
medical histories in the form of quality of life (QoL) questionnaires to evaluate the health of the visual 
system. This trend can be viewed, at least in part, as a means with which to address the discordance 
between high-technology disease assessment and its associated lack of focus on what is practically 
important to patients. While the growing use of vision-specific QoL surveys has provided important 
information about the impact of visual disease from a patient’s perspective, this modality of evaluation 
comes with its own range of limitations. Health-related QoL surveys, including vision-specific 
questionnaires, are influenced by a very broad range of factors including patient personality, individual 
preferences, personal biases, mental health, desire to mislead and desire to please.1-6 In an effort to 
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develop new methods of assessing the visual health of patients, several investigators have developed 
and tested standardized protocols that evaluate the ability of individuals to perform visually-intensive daily 
activities. Although the content of these different investigative techniques tend to vary in the specific 
activities tested, they all have a common focus on detecting changes in very basic and practical visual 
abilities required to perform daily activities. The results of these studies have demonstrated that 
performance-based measures (PBMs) of visual function are valid and reliable measures of visual health.7-
11
 In the same tradition of research, the investigation presented here is intended to validate a third-
generation PBM of visual function titled the “Assessment of Disability Related to Vision” (ADREV) in a 
population of individuals with diabetic retinopathy. 
 
Methods 
Study participants were selected chronologically from individuals receiving care within the general 
ophthalmology clinics and private practices of retinal-vitreous specialists at Wills Eye Institute. Inclusion/ 
exclusion criteria included a diagnosis of either non-proliferative or proliferative diabetic retinopathy (DR), 
written and verbal English proficiency, no visually significant ocular comorbidity and no active visual 
rehabilitation treatments at the time of study participation. Cataract assessment was made using the Lens 
Opacities Classification System II (LOCS II) with exclusion of patients with a 2+ cataract in any 
category.12 Study participants were not to have had retinal photocoagulation treatments within one month 
of study participation. Individuals with medical comorbidities that resulted in significant neurological or 
other systemic manifestations that would have prevented them from completing the study’s protocol were 
also excluded. Patients were selected to reflect a broad range of visual impairment based on better eye 
visual acuity and were identified using a process that included a medical chart review and brief interview. 
All prospective patients were fully informed regarding the details of the study and those who agreed to 
participate completed an informed consent process which was approved by the Wills Eye Institute 
Institutional Review Board (IRB) and in compliance with the Declaration of Helsinki. Study participants 
completed a new third-generation PBM titled the Assessment of Disability Related to Vision (ADREV). 
Patients were also asked to complete the 25-Item National Eye Institute’s Visual Functioning 
Questionnaire (VFQ). All study participants received a standard ophthalmic clinical examination that 
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included monocular and binocular visual acuity assessment using the Early Treatment Diabetic 
Retinopathy Study Lighthouse Chart 2nd edition, Pelli-Robson binocular contrast sensitivity testing, 
monocular 24-2 Humphrey visual fields (HVF) in each eye and a slit-lamp examination including a clinical 
retinal examination in both eyes. Visual acuity measurements were converted to logMAR equivalents 
using the methods employed by The Ischemic Optic Neuropathy Decompression Trial Research Group.13 
Finally, demographic data was collected using a standard form and included age, gender, ethnicity and 
medical comorbidities. 
 
The ADREV instrument is based on a prior investigation involving an alternative PBM titled the 
Assessment of Function Related to Vision (AFREV).14 The AFREV instrument validated five tests of 
performance of visually-intensive tasks based on Item Response Theory in the form of Rasch analysis 
and significant relationships with both traditional clinical measures of opthalmic status, as well as self-
reported vision-specific QoL measured by the National Eye Institute’s Visual Functioning Questionnaire 
(VFQ). The instrument employed within the context of this investigation, titled the ADREV, was developed 
based on the findings of the AFREV experiment and the details of its design have been documented 
elsewhere.15 The ADREV is comprised of 9 tests including: 1) Reading in Reduced Illumination, 2) Facial 
Expression Recognition, 3) Computerized Motion Detection, 4) Recognizing Street Signs, 5) Locating 
Objects, 6) Ambulation, 7) Placing a Peg into Different Sized Holes, 8) Telephone Simulation, and 9) 
Matching Socks. A description of each test item is presented in Figure I: ADREV Test Description. Each 
test of performance is graded from 0 - 7 on an interval scale determined through Rasch analysis; where 0 
represents the inability to perform the test and 7 indicates a perfect score. In addition to the subscale 
evaluations, the nine tests are summed to produce an ADREV total score ranging from 0 – 63. The 
subscales can be employed and interpreted independently from the ADREV total score. Average test 
administration time, including patient instruction is approximately 30 minutes. The ADREV has been 
previously validated in a study population involving patients with age-related macular degeneration 
through comparison with standard clinical measures of visual function and self-reported QoL.16  
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The VFQ was selected as the study’s primary QoL measurement as it is accepted as a reliable and valid 
means of studying the self-perceived impact of visual impairment upon vision-specific QoL.17-19 The VFQ 
is a generic vision-specific instrument that was designed to study a wide variety of ocular diseases and a 
number of studies have used the VFQ to study the self-reported QoL of patients with DR.18-22 The 25-item 
VFQ is comprised of eleven vision-specific subscales that address the following domains: 1) general 
vision, 2) near vision, 3) distance vision, 4) ocular pain, 5) social functioning, 6) mental health, 7) role 
difficulties, 8) dependency, 9) driving, 10) color vision and 11) peripheral vision. Each subscale is scored 
from 0 – 100, where 100 represents self-perceived perfect functioning and 0 represents the greatest level 
of difficulty in a given domain. The eleven subscales are also averaged to produce a VFQ total score 
ranging from 0 – 100. The average test administration time for the VFQ is approximately 10 minutes. 
 
Data analysis was conducted in several steps. First, all variables were plotted and reviewed for outliers 
that might represent data entry errors. Descriptive statistics were computed for demographic, past 
medical, clinical ophthalmic, QoL and PBM measures. Independent t tests were used to determine if any 
differences existed in average VFQ and ADREV total and subscale scoring based on dichotomous 
demographics. Analysis of variance (ANOVA) was conducted to identify statistically significant differences 
in mean VFQ and ADREV total and subscale scores with respect to categorical variables that lacked an 
inherent conceptual hierarchy. Spearman’s rho was used to determine correlative relationships between 
the study’s clinical variables and both the VFQ and ADREV total and subscale scores, as well as between 
the VFQ and ADREV total and subscale scores. Spearman’s nonparametric statistic was chosen to 
standardize comparisons as selected portions of the data provided by the VFQ total and subscale scores 
do not meet the requirements of interval variables.23, 24 Correlation coefficients (r) were considered small 
if less than 0.3, medium between 0.3 and 0.5 and large if greater than 0.5.25  In addition, a robust 
regression analysis using Huber’s Method was used to determine the clinical measures that are most 
associated with each of the ADREV total and subscale scores, while controlling for age, gender, ethnicity 
and total number of medical comorbidities.24 This approach was chosen for several reasons.  Robust 
regression is a valid statistical method for data that meet the criteria for analysis with ordinary least 
squares regression (OLS); however, it is also resistant to the effects of data outliers and can analyze non-
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normally distributed, categorical and binary data.26, 27 All variables were entered into the regression 
equations simultaneously and no automated variable selection process was utilized.  Prior to regression 
equation construction, a correlation matrix using Spearman’s rho was completed using all of the study’s 
independent and control variables to identify and exclude collinear relationships from the regression 
analysis based on correlations of r >/= 0.9.28 Scatterplots were constructed between the measures of 
clinical ophthalmic status and the ADREV total and subscale scores in order to detect any non-linear 
relationships. Independent and control variables were entered into the regression equation irrespective of 
the presence or absence of significant bivariate relationships with ADREV total or subscale scoring. In 
keeping with accepted statistical practice, the number of independent and control variables included in 
each regression equation was equal to or less than 1/10 the total number of cases in our sample 
population.29 Residual statistics for each regression equation were plotted to identify highly significant 
outliers that might have compromised the explanatory power of each regression equation. A 
supplementary bootstrap analysis of 1,000 random resampled data sets was conducted to test the 
external validity of the relationships identified during initial regression modeling.30-32 Where appropriate, all 
statistical tests were run in a two-tailed fashion and corrections for multiple comparisons were made using 
the Bonferroni method.33 A power analysis based on the effect sizes noted in the AFREV experiment 
indicated that a sample population of 90 individuals would be adequate to detect an r = 0.3 with 80% 
power and α = 0.05.14, 34 
 
Results 
Our final sample population consisted of 91 DR patients and the results of our statistical analysis are 
presented in Appendix II. The average age of participants was 61 with a standard deviation (SD) of +/- 11 
years. The study population had slightly unequal representation based on gender with 35% (n = 32) being 
male. There were nearly equal numbers of individuals from European (n = 47) and African extraction (n = 
40), with the remainder of the group being comprised of three Hispanic individuals and one person of 
Asian descent. The average number of medical comorbidities was 2.7 (SD +/- 1.6). The five most 
common comorbidities included hypertension (59.3%), hypothyroidism (20.9%), hypercholesteremia 
(6.6%), osteoarthritis (6.6%) and hyperthyroidism (6.6%). The population consisted of 178 eyes 
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diagnosed with DR with seventy three eyes (41%) having a diagnosis of non-proliferative DR, while the 
remaining one hundred and five eyes (59%) had a diagnosis of proliferative DR. Descriptive statistics of 
the study populations’ clinical ophthalmic assessments, ADREV and VFQ total and subscale scores are 
presented in Table I. The study group included a wide range of better eye visual acuity measurements 
ranging from 20/20 through to NLP. Worse eye visual field MD values were equally varied and included 
individuals with full visual fields through to end stage peripheral visual loss. ADREV total and subscale 
scores represented the full range of possible scoring. VFQ total and subscale scores were similar to the 
results published by Tranos et al. (2004), but somewhat lower than those published by Klien et al 
(2001).20, 21  A comparison of mean ADREV total and subscale scores with respect to gender revealed 
only one significant difference with females scoring slightly higher (5.85) than males (5.19) on the 
Ambulation test. There were no significant relationships between patient performance on the ADREV total 
and subscale scores based on age, number of comorbid medical conditions or self-reported ethnicity.  
 
Bivariate analysis between the study’s’ clinical variables and the ADREV total and subscale measures 
demonstrated that 53 of the total 60 (88%) comparisons were significant to p < 0.05 (Table II). After 
adjustment for multiple comparisons, 49 of the 60 comparisons (82%) were statistically significant to p < 
0.0007 (Table II). After correction for multiple comparisons, all but one of the ADREV’s scales were 
correlated with one or more of the clinical measures of visual function with only the Ambulation test 
having no significant bivariate correlation to the clinical measures. The four strongest relationships 
included: 1) binocular visual acuity and ADREV total score (r = -.780); 2) binocular visual acuity and 
Recognizing Street Signs (r = -.772); 3) better eye visual acuity and Recognizing Street Signs (r = -. 731); 
and 4) better eye visual acuity and ADREV total score (r = -.725). The mean absolute correlation 
magnitude for all significant relationships between the ADREV, its subscales and all clinical measures 
was r .515 (SD +/- .108).  
 
In contrast, the correlative analysis between the VFQ total and subscale scores with the study’s clinical 
measures of visual function revealed 63 of the 72 comparisons (88%) were significant to p < 0.05. After 
adjustment for correction for multiple comparisons, fifty two of the seventy two comparisons (72%) were 
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statistically significant to p < 0.0006. The strongest four relationships were: 1) better eye visual acuity and 
Mental Health (r = -.550); 2) worse eye visual acuity and VFQ total score (r = -.542); 3) worse eye MD and 
VFQ total score (r = .538); and 4) better eye visual acuity and VFQ total score (r = -.533). The mean 
absolute correlation magnitude between the VFQ, its subscales and all of the clinical measures was r = 
.438 (SD +/- .054). A one sample t test between the mean absolute correlation magnitude for all 
significant correlative relationships between the ADREV-clinical measures analysis and the VFQ-clinical 
measures analysis revealed that the higher mean correlations between the ADREV and the clinical 
measures was statistically significant (p < 0.001). 
 
Table IV summarizes a direct comparison between the ADREV and VFQ total and subscale scores. Initial 
analysis revealed that 81 of the 120 comparisons (68%) were significant to p < 0.05. After correction for 
multiple comparisons, 42 relationships (35%) were significant to p < 0.0004. The four strongest 
correlations were between: 1) Motion Detection and VFQ total score (r = .523); 2) Motion Detection and 
Near Activities (r = .520); 3) Facial Expression Recognition and VFQ total score (r = .514); and 4) Facial 
Expression Recognition and Mental Health (r = .501). The mean absolute correlation magnitude between 
the ADREV and VFQ total and subscale scores was r = .431 (SD +/- .048). 
 
 The results of the robust regression analysis between the ADREV total and subscale scores and the 
study’s clinical variables are presented in Table V. Prior to building each equation, a correlation matrix of 
the study’s clinical variables indicated that binocular visual acuity and better eye visual acuity had a 
correlation coefficient equal to 0.9. Based on this exceptionally strong relationship, as well as the related 
nature of the two measures, this finding was interpreted to mean that the two assessments were 
measuring the same phenomenon. In cases where both binocular visual acuity and better eye visual 
acuity were correlated with the ADREV total or subscale scores, the measure with the stronger 
relationship was included in the regression equation. Scatterplot analysis did not reveal any non-linear 
relationships. No data was removed following residual statistical analysis. For each of the ADREV’s total 
and subscale scores, the statistically significant independent variables predictive of patient performance 
are presented in Table V in order of beta weight magnitude. Independent variables that remained 
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significant within the 95% CI following bootstrap analysis are also presented in Table V.  The results of 
the regression analysis indicated that binocular visual acuity, binocular contrast sensitivity and better eye 
visual field are all significantly related to the performance of DR patients on the ADREV, irrespective of 
age, gender, ethnicity or total number of medical comorbidities. 
 
Discussion 
This study had several limitations. To begin, all individuals were recruited from a single tertiary ophthalmic 
hospital and it may not be possible to validly generalize our findings to all individuals. Study participants 
completed approximately two hours of testing as part of the study protocol and fatigue may have 
influenced the results of our testing. Indicators of clinical depression were not collected and individuals 
suffering from clinical depression may have influenced the reported scores on the VFQ.3, 35 The study 
population size was also limited to ninety one individuals and it is possible that additional, weaker 
relationships were not detected. Our inclusion/ exclusion criteria removed all individuals with ocular 
comorbidity, as well as any serious musculoskeletal or neurological impairment that might have 
influenced their testing results and this may limit the applicability of our results to all patient sub-
populations. Furthermore, other clinical measures of visual function such as stereopsis, glare testing and 
color vision were not completed by the study population and there may be additional associations 
between these measures and the ADREV that were not measured by this investigation. It should also be 
acknowledged that while the activities chosen for the ADREV are commonly encountered in daily living, 
not all individuals will perform these activities or value them to the same extent. Others have elected to 
have patients weigh the importance of each activity used in performance testing and this approach could 
be employed to improve future versions of the ADREV.36  
 
Despite these potential limitations, the results of our investigation support the validity of the ADREV 
performance measure for assessing visual ability in patients with diabetic retinopathy. Strong to moderate 
bivariate associations existed between multiple measures of clinical ophthalmic status, as well as self-
reported vision-specific QoL. Moreover, in comparison to vision-specific QoL measured by the VFQ, the 
ADREV PBM shared a significantly stronger relationship to all of the traditional measures of clinical 
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assessment. Regression analysis demonstrated that each of the clinical measures of visual function 
including visual acuity, contrast sensitivity and visual field remained highly associated with ADREV total 
and subscale scoring, after controlling for age, gender, ethnicity and medical comorbidity. Importantly, 
however, while the relationships noted between traditional measures of ophthalmic status and the 
ADREV were large in magnitude, they were not large enough to validly infer that traditional ophthalmic 
measures can be used as surrogates for the evaluations provided by the ADREV. Though highly related, 
the moderate to strong relationships noted in this study between traditional clinical measures of visual 
function and ADREV performance provide support to the notion that measurements of actual patient 
performance provide qualitatively different information than surrogate measures of functional performance 
such as visual acuity, contrast sensitivity or visual field measurements. 
 
All of the relationships fit well with our current understanding of the types of visual abilities affected by 
patients with DR. The role of better eye visual field in the ability to correctly match socks from a presented 
selection likely relates to the ability to simultaneously survey several different items in order to correctly 
match similar items. Individuals with “tunnel vision” due to a constricted visual field would be less able to 
simultaneously compare the visual qualities of multiple items that need to be viewed across a larger 
expanse of visual field. The importance of central visual acuity in reading, facial recognition, reading 
street signs and dialing a telephone is readily apparent. Similarly, the relationship found between better 
eye visual field and motion detection is well supported by prior research.37 The role of contrast sensitivity 
appeared important when performing a number of different activities. Contrast sensitivity proved to be 
related to the ability to discern significant detail, including facial expression recognition and placing a peg 
into a small hole; yet also had an important association with the ability to locate objects in a room.  These 
findings are consistent with the types of visual loss that patients with DR often experience related to not 
only the natural history of the disease, but also to the reduction in peripheral vision associated with retinal 
photocoagulation used to preserve central visual function. These findings emphasize the multi-faceted 
nature of the visual abilities required to function in day to day living and the many different visual 
challenges faced by patients with DR. 
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In comparison to the previous investigation involving the ADREV and patients with AMD we noted similar 
absolute mean correlative bivariate relationships between the ADREV total and subscale scores and 
clinic measures of visual function (DR r = 0.515, AMD r = 0.569).16 A number of similarities were also 
noted between the strongest bivariate relationships when comparing the clinical measures of visual 
impairment and ADREV performance in both the DR and AMD populations. Specifically, binocular visual 
acuity and better eye visual acuity were most related to ADREV scoring in both the DR and AMD groups. 
Comparison of the results of regression analysis between the AMD and DR populations showed similar 
associations relating binocular visual acuity and contrast sensitivity to ADREV total and subscale 
performance. However, unlike the AMD population, the DR population showed a significant relationship 
between ADREV total and subscale performance and better eye visual field. The latter relationship likely 
relates to DR patients who have peripheral visual field loss following pan-retinal photocoagulation for 
proliferative disease. 
 
The value of performance measures lies in the clear content validity of the data they provide. Patients are 
deeply aware of how their illness affects their ability to perform activities that matter to them. In this 
regard, the information provided by performance-based assessment is unique. Performance measures 
provide a standardized and valid means of assessing visual disease, while simultaneously providing an 
evaluation that carries far more importance to patients than traditional clinical, laboratory or imaging 
assessments. From this perspective, PBMs are able to bridge the gap between the goals of self-reported 
evaluations aimed at ascertaining the importance of disease impact to patients, and the standardized 
character of traditional measures of visual function taken in an office setting. It is hoped that PBMs will 
serve as means with which to acquire the best of both of these assessments, while avoiding many of the 
confounding factors of self-report, as well as the irrelevant quality of many of the traditional measures of 
visual function. For these reasons future investigators should consider utilizing PBMs of visual ability in 
vision research and ophthalmic practice. 
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Table I: Clinical, Assessment of Disability Related to Vision and Visual Functioning 
Questionnaire Descriptive Statistics in Patients with Diabetic Retinopathy 
Clinical Variables Mean Median SD Skew Range n 
Binocular Visual Acuity .358 .300 1.66 .279 0 – 1.9 91 
Better Eye Visual Acuity .406 .340 .350 2.65 0 – 1.9 91 
Worse Eye Visual Acuity .829 .620 .682 1.46 0 – 2.8 91 
Contrast Sensitivity 1.25 1.25 .272 -1.28 .15 - 1.65 91 
Mean Deviation Better Eye -9.81 -7.78 7.16 -1.03 -28.96 - -.06 91 
Mean Deviation Worse Eye -13.92 -10.38 -10.38 -.893 -40 - -1.0 91 
Assessment of Disability Related to 
Vision Total Score 44.1 45.8 9.96 -.89 15 - 61 91 
Reading in Reduced Illumination 5.0 5.0 1.63 -.62 0 - 7 91 
Facial Expression Recognition 4.7 5.0 1.81 -.81 0 - 7 91 
Motion Detection 5.3 5.0 1.14 -.01 2 -7 91 
Recognizing Street Signs 3.8 4.0 1.58 -.70 0 - 6 91 
Locating Objects 5.0 5.5 1.28 -.73 2 - 7 91 
Ambulation 5.6 5.7 .97 -1.45 2 - 7 91 
Placing Peg into Holes 4.6 5.0 1.61 -.47 0 - 7 91 
Telephone Simulation 5.1 5.0 1.83 -.93 0 - 7 91 
Matching Socks 5.0 6.0 2.25 -.80 0 - 7 91 
Visual Functioning Questionnaire Total 
Score 70.0 72.5 18.78 -.66 20 - 98 91 
General Vision 61.7 60.0 18.77 -.43 20 - 100 91 
Ocular Pain 78.3 87.5 20.82 -.71 13 – 100 91 
Near Activities 61.5 58.3 23.23 -.03 8 - 100 91 
Distance Activities 67.5 66.7 22.8 -.43 17 - 100 91 
Social Functioning 81.2 87.5 22.3 -1.25 13 - 100 91 
Mental Health 64.1 68.8 27.0 -.76 0 - 100 91 
Role Difficulties 59.2 62.5 32.0 -.24 0 - 100 90 
Dependency 78.0 75.0 27.1 -1.24 0 - 100 91 
Driving 68.9 75.0 27.1 -1.24 0 - 100 54 
Color Vision 82.7 100 22.6 -1.12 25 - 100 91 
Peripheral Vision 69.2 75.0 26.9 -.24 25 - 100 91 
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Table II: Assessment of Disability Related to Vision vs. Clinical Measures in Patients with Diabetic Retinopathy 
(Spearman’s Rho) 
 
Binocular 
Visual Acuity  
(n) 
Better Eye 
Visual Acuity 
(n) 
Worse Eye 
Visual Acuity  
(n) 
Contrast 
Sensitivity 
(n) 
Better Eye 
Mean Deviation 
(n) 
Worse Eye 
Mean Deviation 
(n) 
Assessment of 
Disability 
Related to 
Vision 
-.780* 
(91) 
-.725* 
(91) 
-.566* 
(91) 
.610* 
(91) 
.571* 
(91) 
.564* 
(91) 
Reading in 
Reduced 
Illumination 
-.418* 
(91) 
-.337 
(91) 
-.280 
(91) 
.143 
(91) 
.190 
(91) 
.169 
(91) 
Facial 
Expression 
Recognition 
-.667* 
(91) 
-.637* 
(91) 
-.491* 
(91) 
.549* 
(91) 
.417* 
(91) 
.487* 
(91) 
Motion 
Detection 
-.538* 
(91) 
-.519* 
(91) 
-.458* 
(91) 
.475* 
(91) 
.624* 
(91) 
.508* 
(91) 
Recognizing 
Street Signs 
-.772* 
(91) 
-.731* 
(91) 
-.404* 
(91) 
.603* 
(91) 
.559* 
(91) 
.436* 
(91) 
Locating 
Objects 
-.636* 
(91) 
-.605* 
(91) 
-.472* 
(91) 
.519* 
(91) 
.469* 
(91) 
.537* 
(91) 
Ambulation -.226 (91) 
-.218 
(91) 
-.031 
(91) 
.153 
(91) 
.105 
(91) 
.137 
(91) 
Placing Peg in 
Holes 
-.397* 
(91) 
-.411* 
(91) 
-.408* 
(91) 
.441* 
(91) 
.363* 
(91) 
.418* 
(91) 
Telephone 
Simulation 
-.623* 
(91) 
-.560* 
(91) 
-.446* 
(91) 
.473* 
(91) 
.424* 
(91) 
.394* 
(91) 
Matching Socks -.491* (91) 
-.464* 
(91) 
-.373* 
(91) 
.395* 
(91) 
.452* 
(91) 
.371* 
(91) 
Bonferroni method used for adjustments for multiple comparisons. *p<0.05 p>0.05 
 16/22 
Table III: Correlative Analysis – Visual Functioning Questionnaire vs. Clinical Measures in Patients with Diabetic 
Retinopathy (Spearman’s Rho) 
 
Binocular 
Visual Acuity  
(n) 
Better Eye 
Visual Acuity 
(n) 
Worse Eye 
Visual Acuity  
(n) 
Contrast 
Sensitivity 
(n) 
Better Eye 
Mean Deviation 
(n) 
Worse Eye 
Mean Deviation 
(n) 
Visual 
Functioning 
Questionnaire 
-.502* 
(91) 
-.533* 
(91) 
-.542* 
(91) 
.497* 
(91) 
.470* 
(91) 
.538* 
(91) 
General Vision -.456* (91) 
-.512* 
(91) 
-.396* 
(91) 
.378* 
(91) 
.317 
(91) 
.437* 
(91) 
Ocular pain -.177 (91) 
-.102 
(91) 
-.126 
(91) 
.060 
(91) 
-.005 
(91) 
.053 
(91) 
Near Activities -.401* (91) 
-.476* 
(91) 
-.475* 
(91) 
.400* 
(91) 
.458* 
(91) 
.409* 
(91) 
Distance 
Activities 
-.390* 
(91) 
-.419* 
(91) 
-.390* 
(91) 
.388* 
(91) 
.335 
(91) 
.331 
(91) 
Social 
Functioning 
-.421* 
(91) 
-.425* 
(91) 
-.399* 
(91) 
.377 
(91) 
.377* 
(91) 
.414* 
(91) 
Mental Health -.519* (91) 
-.550* 
(91) 
-.462* 
(91) 
.399* 
(91) 
.348 
(91) 
.526* 
(91) 
Role Difficulties -.418* (91) 
-.461* 
(91) 
-.476* 
(91) 
.392* 
(91) 
.389* 
(91) 
.390* 
(91) 
Dependency -.410* (91) 
-.405* 
(91) 
-.390* 
(91) 
.238 
(91) 
.314 
(91) 
.403* 
(91) 
Driving -.208 (91) 
-.288 
(91) 
-.184 
(91) 
.240 
(91) 
.362 
(91) 
.342 
(91) 
Color Vision -.372* (91) 
-.397* 
(91) 
-.323 
(91) 
.373* 
(91) 
.351 
(91) 
.392* 
(91) 
Peripheral 
Vision 
-.311 
(91) 
-.312 
(91) 
-.515* 
(91) 
.448* 
(91) 
.430* 
(91) 
.516* 
(91) 
Bonferroni method used for adjustments for multiple comparisons. *p < 0.05 p > 0.05 
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Table IV: Correlative Analysis – Assessment of Disability Related to Vision vs Visual Functioning Questionnaire in Patients with 
Diabetic Retinopathy (Spearman’s Rho) 
 
 VFQ† 
(n) 
GV† 
(n) 
OP† 
(n) 
NA† 
(n) 
DA† 
(n) 
SF† 
(n) 
MH† 
 (n) 
RD† 
(n) 
DP† 
(n) 
DR† 
(n) 
CV† 
(n) 
PV† 
(n) 
Assessment of 
Disability 
Related to 
Vision 
.496* 
(91) 
.453* 
(91) 
.152 
(91) 
.419* 
(91) 
.308* 
(91) 
.429* 
(91) 
.499* 
(91) 
.415* 
(91) 
.438* 
(91) 
.290 
(54) 
.310 
(91) 
.299 
(91) 
Reading in 
Reduced 
Illumination 
.163 
(91) 
.058 
(91) 
.224 
(91) 
.108 
(91) 
.053 
(91) 
.130 
(91) 
.231 
(91) 
.111 
(91) 
.188 
(91) 
.243 
(54) 
-.006 
(91) 
.052 
(91) 
Facial 
Expression 
Recognition 
.514* 
(91) 
.471* 
(91) 
.211 
(91) 
.415* 
(91) 
.383* 
(91) 
.418* 
(91) 
.501* 
(91) 
.418* 
(91) 
.326 
(91) 
.273 
(54) 
.415* 
(91) 
.331 
(91) 
Motion 
Detection 
.523* 
(91) 
.411* 
(91) 
.172 
(91) 
.520* 
(91) 
.378* 
(91) 
.439* 
(91) 
.399* 
(91) 
.432* 
(91) 
.471* 
(91) 
.471* 
(54) 
.398* 
(91) 
.317 
(91) 
Recognizing 
Street Sings 
.412* 
(91) 
.461* 
(91) 
-.043 
(91) 
.363* 
(91) 
.305 
(91) 
.351 
(91) 
.432* 
(91) 
.303 
(91) 
.334 
(91) 
.229 
(54) 
.299 
(91) 
.319 
(91) 
Locating 
Objects 
.473* 
(91) 
.449* 
(91) 
.142 
(91) 
.308 
(91) 
.324 
(91) 
.436* 
(91) 
.483* 
(91) 
.369* 
(91) 
.383* 
(91) 
.258 
(54) 
.326 
(91) 
.342 
(91) 
Ambulation .113 (91) 
.075 
(91) 
.161 
(91) 
.144 
(91) 
.115 
(91) 
.216 
(91) 
.044 
(91) 
.094 
(91) 
-.014 
(91) 
.146 
(54) 
.001 
(91) 
-.031 
(91) 
Placing Peg in 
Holes 
.183 
(91) 
.218 
(91) 
-.086 
(91) 
.229 
(91) 
.124 
(91) 
.198 
(91) 
.217 
(91) 
.173 
(91) 
.200 
(91) 
.044 
(54) 
.066 
(91) 
.116 
(91) 
Telephone 
Simulation 
.459* 
(91) 
.420* 
(91) 
.243 
(91) 
.377* 
(91) 
.291 
(91) 
.390* 
(91) 
.408 
(91) 
.354 
(91) 
.382* 
(91) 
.208 
(54) 
.346 
(91) 
.314 
(91) 
Matching 
Socks 
,357 
(91) 
.259 
(91) 
.060 
(91) 
.327 
(91) 
.183 
(91) 
.326 
(91) 
.336 
(91) 
.370* 
(91) 
.358 
(91) 
.130 
(54) 
.232 
(91) 
.237 
(91) 
†
 VFQ = VFQ total score; GV = general vision; OP = Ocular Pain; NA = Near Activities; DA = Distance Activities; SF = Social 
Functioning; MH = Mental Health; RD = Role Difficulties; DP = Dependency; DR = Driving; CV = Color Vision; PV = Peripheral 
Vision 
Significance levels adjusted for multiple comparisons using the Bonferroni method. *p < 0.05 p > 0.05 
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Table V: Robust Regression (Huber’s Method: C=1.345)  – Assessment of Disability Related to Vision vs Clinical Measures in 
Patients with Diabetic Retinopathy 
Dependent Variables Independent Variables (x) = beta weight (95% CI)* Bootstrap† n 
Binocular Visual Acuity = -12.4 (-16.4 - - 8.3), Contrast Sensitivity = 7.6 ( 2.5 – 12.6), Worse 
Eye Visual Acuity = -2.4 (-4.4 - - 0.3), Better Eye Mean Deviation = 0.3 (0.1 – 0.5) - 91 Assessment of Disability Related to 
Vision Binocular Visual Acuity = -13.6 (-18.2 - - 0.3), Contrast Sensitivity = 7.2 (0.4 - 15.4),  + 91 
Binocular Visual Acuity = -2.6 (-3.9 - -1.3) - 91 Reading in Reduced 
Illumination Binocular Visual Acuity = - 2.4 (-5.2 - - 1.1) + 91 
Binocular Visual Acuity = -2.3 (-3.3 - -1.3), Contrast Sensitivity = 1.8 (0.5 – 3.0) - 91 Facial Expression 
Recognition Binocular Visual Acuity = -2.4 (-4.2 - - 0.3), Contrast Sensitivity = 1.6 (0.006 – 4.0) + 91 
Better Eye Mean Deviation = 0.1 (0.02 – 0.1) - 91 
Motion Detection 
Better Eye Mean Deviation = 0.1 (0.01 – 0.1) + 91 
Binocular Visual Acuity = -3.2 (-4.1 - -2.4), Better Eye Mean Deviation = 0.1 (0.02 – 0.09) - 91 Recognizing Street 
Signs Binocular Visual Acuity = -3.3 (-4.7 - -1.2), Better Eye Mean Deviation = 0.1 (0.01 – 0.1) + 91 
Contrast Sensitivity = 1.3 (0.4 – 2.2), Binocular Visual Acuity = -1.1 (-1.8 - -0.4), Worse Eye 
Mean Deviation = 0.05 (0.02 – 0.08) - 91 Locating Objects 
Contrast Sensitivity = 1.2 (0.5 – 2.7), Worse Eye Mean Deviation = 0.04 (0.01 – 0.11) + 91 
Contrast Sensitivity = 2.0 (0.7 – 3.4), Better Eye Visual Acuity = -1.0 (-1.9 - -0.02) - 91 
Placing Peg in Holes 
Contrast Sensitivity = 1.8 (0.7 – 4.0) + 91 
Binocular Visual Acuity = -2.6 (-3.7 -  -1.5), Worse Eye Visual Acuity = -0.6 (-1.6 -  -0.1) - 91 
Telephone Simulation 
Binocular Visual Acuity = -2.4 (-5 -  - 1.3) + 91 
Better Eye Mean Deviation = 0.1 ( 0.03 – 0.18) - 91 
Matching Socks 
Better Eye Mean Deviation = 0.1 (0.01 – 0.25) + 91 
*Independent variables presented are significant to p </ = 0.05 after controlling for age, gender, ethnicity and no. of medical comorbidities. 
† Estimates made using a resampling of 1,000 random data sets and displayed variables are significant within 95% confidence intervals. 
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Table VI: Assessment of Disability Related to Vision Test Description 
1. Reading in reduced illumination 
Near vision is checked by obtaining the smallest Jaeger line, then one at a time, 7 sentences, text size 
corresponding to 2 Jaeger lines above the smallest Jaeger read, are presented. Light illumination is 
reduced after each sentence is read. The corresponding score is as follows: 1 point, able to read at 200 
foot candles (FC), 2 at 150 FC, 3 at 100 FC, 4 at 50 FC, 5 at 25 FC, 6 at 10 FC and 7 at 5 FC. The 
highest score is 7 and lowest score is 0.  
 
2. Facial expression recognition 
Seven full-face professional, colored photos of varying sizes and facial expressions (angry, sad, happy, or 
surprised) are presented on a computer screen at a distance of 1/2 meter. The patient receives one point 
for recognizing the right facial expression. Score ranged from 7 to 0. 
 
3. Computerized Motion Detection 
A large black cross against a white background on a computer screen provides a point of fixation. While 
fixating on the cross, one at a time, 14 balls of different sizes and colors move diagonally across the 
screen from either the right or the left side at a constant speed.  Yellow, red, or blue balls are used.  The 
patient is asked to count the number of moving balls. Each ball seen counts as ½ point. Highest score is 
7 and lowest score is 0. 
 
4. Recognizing street signs  
Seven written word signs ranging from large to small are read at a distance of 4 meters. One character in 
each sign, was changed from familiar phrases making the word difficult to guess. For example, the top 
sign reads SUGAR DANE, which is similar to the more familiar sugar cane. The patient is instructed not to 
guess. One point is given for each sign read correctly. Highest score is 7 and lowest score is 0.  
 
5. Locating objects 
Fourteen red and beige boxes of different sizes are scattered around the testing room (4 x 2 meters). 
Sample boxes are shown before test started. The patient attempts to locate the boxes while seated. Each 
box found is worth ½ point.  Highest score will be 7 and lowest 0.  
 
6. Ambulation test 
A 4.5 meter predefined mobility course was designed, with taped horizontal, vertical and diagonal lines 
and objects made of styrofoam in the path. Several objects were also suspended from the ceiling along 
the path. Patients were permitted to use a mobility aid (e.g. cane).  
 The score is based on number of obstacles hit.  Each obstacle successfully avoided was awarded 1/3 
point.  The highest score is 7 and lowest is 0.  
 
7. Placing a peg into different sized holes  
Seven (9x3x3/8 inches) wooden boards were created with 1 hole of varying sizes and location. A wooden 
stand was created with slots to hold the boards one at time at different angles. The patient is asked to 
place the peg directly in the hole without touching the board. One point is awarded for successful 
completion. 
 
8. Telephone simulation 
Seven calculators of different sizes are used to simulate dialing a telephone. The numbers are randomly 
rearranged to eliminate memory being used to locate the telephone numbers. The numbers are printed 
from different font sizes and presented to patients from largest to smallest. The patient is asked to press 
seven different numbers on each of the various sized calculators. The patient must find all seven 
numbers to receive a point for that calculator.  For each number correctly “dialed”, the patient receives 
one point. The highest score is 7 and lowest 0. 
 
9. Matching socks 
Seven differently patterned, dark-colored socks were hung on a board with a grey background. The 
patients are not permitted to touch the socks hanging on the wall. The patient sits in front of a table 1 
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meter wide so as to be 1 meter from the socks. On the table is a group of 10 socks, 7 of which are the 
pairs for the hanging socks. The patient is asked to match the socks on the table with those on the board. 
One point is awarded for each correctly matched sock. The highest score is 7 and lowest 0. 
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